Work

Rationale for a Phase II Trial of Pertuzumab, a HER-2 Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer

Year: 2006

Type: article

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-06-0629

Authors: Bruce E. Johnson, Pasi A. Jänne

Institutions: Brigham and Women's Hospital, Harvard University, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2098669538

FWCI: 4.56

Cites: 31

Cited by: 40

Related to: 10